-+ 0.00%
-+ 0.00%
-+ 0.00%

Health Canada Grants No Objection Letter for AbCellera's ABCL575, Advancing Investigational OX40L Antibody For AD Treatment

Benzinga·05/30/2025 17:02:48
Listen to the news

ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis

AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025

AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions.

The Phase 1 study is anticipated to begin in Q3 of 2025 and will evaluate the safety and pharmacokinetics of ABCL575 administered subcutaneously in healthy participants.